TY  - JOUR
T1  - Significant Infusion-associated reaction during first dose Alemtuzumab Treatment
TT  - Doz Alemtuzumab Tedavisinde Ciddi Karaciğer Enzim Yüksekliği
AU  - Gözübatık Çelik, Rabia Gökçen
AU  - Öztürk, Musa
AU  - Başoğlu Koseahmet, Fulya
PY  - 2021
DA  - November
Y2  - 2021
JF  - Tıp Fakültesi Klinikleri Dergisi
JO  - TFK
PB  - İstanbul Aydın Üniversitesi
WT  - DergiPark
SN  - 2630-5585
SP  - 163
EP  - 167
VL  - 4
IS  - 3
LA  - en
AB  - There are many new treatments in Multiple Sclerosis (MS), such as monoclonal antibodies. Weaimed to report the expected but crucial side effects of alemtuzumab treatment for the first time.A 32 years old female with MS had been received alemtuzumab; after therapy, 17-times increaseof liver enzymes called fatal level was detected in blood tests. It could be caused by transientcell activation and infusion associated reactions (IARs). The side effects of monoclonal antibodytreatments can be fatal to the patient, even if known.
KW  - Multiple-sclerosis
KW  - Alemtuzumab
KW  - Side effect
KW  - Hypertransaminasemia
N2  - AMAÇ: Multipl Sklerozda (MS) monoklonal antikorlar gibi birçok yeni tedavi vardır. Bu olgu ile Alemtuzumab tedavisinin önemli bir yan etkisini bildirmeyi amaçladık.OLGU: 32 yaşında kadın MS hastası alemtuzumab infüzyonu aldı.  İlk doz sonrası yapılan kan testlerinde hayati tehlikeye neden olabilen karaciğer enzimlerinde 17 kat artış tespit edildi. Bu durum geçici hücre aktivasyonundan ve İnfüzyonla İlişkili Reaksiyonlardan (IAR'ler) kaynaklandığı düşünüldü.SONUÇLAR: Monoklonal antikor tedavilerinin yan etkileri bilinmekle birlikte bu durumun fatal olabileceği her zaman akılda tutulmalı, gerekli önlemler alınmalıdır
CR  - (1) Havla J, Warnke C, Derfuss T, Kappos L, Hartung H-P, Hohlfeld R. Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.  Deutsches Ärzteblatt International, 2016;13(51-52):879-86. https://doi: 10.3238/arztebl.2016.0879.
CR  - (2) Al-Sawaf O, Fischer K, Herling CD, Ritgen M, Böttcher S, Bahlo J et al.  Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. Eur J Haematol,  2017; 98(3):254-62. https://doi: 10.1111/ejh.12825.
CR  - (3) Thomas K, Eisele J, Rodriguez-Lea FA, Hainke U, Ziemssen T. Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm, 2016; 3(3): e228. https://doi: 10.1212/NXI.0000000000000228
CR  - (4) Sandra Vukusic S, Brassat D, Seze J, Izquierdo G, Lysandropoulos A, Moll W, Vanopdenbosch L, Arque MJ, Kertous M, Rufi P, Oreja-Guevara C. Single-Arm Study to Assess Comprehensive Infusion Guidance for the Prevention and Management of the Infusion Associated Reactions (IARs) in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With Alemtuzumab (EMERALD) Mult Scler. Relat. Disord. 2019; 29:7-14 doi: https://doi.org/10.1016/j.msard.2019.01.019
CR  - (5) Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 2014;10:124(2):188-5.  https://doi: 10.1182/blood-2014-05-552729.
UR  - https://dergipark.org.tr/tr/pub/atk/issue//955269
L1  - https://dergipark.org.tr/tr/download/article-file/1834783
ER  -